An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis
- PMID: 11397142
- DOI: 10.1021/jo001442w
An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis
Abstract
People continue to smoke and use tobacco products despite well-established hazardous consequences. The most contributing factor is the addictive nature of nicotine. There is no highly effective treatment for the problem of nicotine dependence. Immunotherapy offers an alternative to conventional approaches. The chemistry necessary for a comprehensive immunopharmacological program is presented. Haptens for the generation of antibodies specific for naturally occurring (S)-nicotine, (S)- and (R)-nornicotine, and the metabolite (S)-cotinine were prepared with high optical purity. Preliminary data for antinicotine antibodies are reported.
Similar articles
-
Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.Vaccine. 2010 Mar 2;28(10):2161-2168. doi: 10.1016/j.vaccine.2009.12.051. Epub 2010 Jan 7. Vaccine. 2010. PMID: 20060511
-
Positional linker effects in haptens for cocaine immunopharmacotherapy.Bioorg Med Chem Lett. 2007 Aug 1;17(15):4280-3. doi: 10.1016/j.bmcl.2007.05.032. Epub 2007 May 16. Bioorg Med Chem Lett. 2007. PMID: 17531484
-
The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.Vaccine. 2015 Nov 17;33(46):6332-9. doi: 10.1016/j.vaccine.2015.09.015. Epub 2015 Sep 26. Vaccine. 2015. PMID: 26409811 Free PMC article.
-
Pharmacology of nicotine: addiction and therapeutics.Annu Rev Pharmacol Toxicol. 1996;36:597-613. doi: 10.1146/annurev.pa.36.040196.003121. Annu Rev Pharmacol Toxicol. 1996. PMID: 8725403 Review.
-
Biotechnology and the treatment of addictive disorders: new opportunities.BioDrugs. 2007;21(4):259-67. doi: 10.2165/00063030-200721040-00006. BioDrugs. 2007. PMID: 17628123 Review.
Cited by
-
New directions in nicotine vaccine design and use.Adv Pharmacol. 2014;69:553-80. doi: 10.1016/B978-0-12-420118-7.00014-7. Adv Pharmacol. 2014. PMID: 24484987 Free PMC article. Review.
-
Immunotherapies for the Treatment of Drug Addiction.Vaccines (Basel). 2022 Oct 22;10(11):1778. doi: 10.3390/vaccines10111778. Vaccines (Basel). 2022. PMID: 36366287 Free PMC article. Review.
-
A New Strategy for Smoking Cessation: Characterization of a Bacterial Enzyme for the Degradation of Nicotine.J Am Chem Soc. 2015 Aug 19;137(32):10136-9. doi: 10.1021/jacs.5b06605. Epub 2015 Aug 6. J Am Chem Soc. 2015. PMID: 26237398 Free PMC article.
-
The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.BMC Public Health. 2012 Dec 6;12:1052. doi: 10.1186/1471-2458-12-1052. BMC Public Health. 2012. PMID: 23216646 Free PMC article. Clinical Trial.
-
Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.Biochem Pharmacol. 2012 Feb 15;83(4):543-50. doi: 10.1016/j.bcp.2011.11.004. Epub 2011 Nov 15. Biochem Pharmacol. 2012. PMID: 22100986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical